A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2

Trial Profile

A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2

Discontinued
Phase of Trial: Phase III

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Brodalumab (Primary) ; Ustekinumab
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms AMAGINE-2
  • Sponsors Amgen
  • Most Recent Events

    • 12 Oct 2017 Results of polled analysis of AMAGINE 2 and 3 trial presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
    • 12 Oct 2017 Results from long-term extension portion of this trial published in an Ortho Dermatologics Media Release
    • 12 Oct 2017 According to an Ortho Dermatologics media release, data from long-term extension portion of this trial is being presented at the 2017 Fall Clinical Dermatology Conference
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top